|
Hsue PY, Tawakol. A et al. IL-1β Inhibition Reduces Atherosclerotic Inflammation in HIV Infection. Journal of the American College of Cardiology 2018.
In a pilot study, Dr. Tawakol and colleagues assessed bone marrow activity and arterial inflammation using FDG-PET/CT alongside multiparametric assessments of systemic inflammation and immune cell activation in 10 individuals living with HIV to test the hypotheses that IL-1β inhibition reduces immune activation and atherosclerotic plaque inflammation. This first report using FDG-PET/CT to measure the effect of IL-1β inhibition on arterial wall inflammation and the first study of a potent immune-based regimen showed that a single dose of monoclonal antibody to IL-1β (canakinumab) significantly reduced inflammatory markers, arterial inflammation, and leukopoietic activity in HIV.
Figure: Fluorodeoxyglucose–Positron-Emission Tomography/Computed Tomography Before and After Interleukin-1β Inhibition with Canakinumab.
|
|
|
|
Mahmood SS, Neilan TG et al. Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. Journal of the American College of Cardiology 2018.
Dr. Neilan and colleagues created the first multicenter registry to study myocarditis following therapy with immune checkpoint inhibitors (ICI) as a potentially important adverse effect of treatment with this novel category of drugs that help direct the immune system to recognize and target cancer cells. The registry included 35 patients with ICI-associated myocarditis, who were compared to a random sample of 105 ICI-treated patients without myocarditis at 8 sites from November 2013 to July 2017. The study established that the prevalence of myocarditis may be higher than anticipated (1%) and occurs early after starting treatment (median time of onset: 34 days after starting ICI). Moreover, ICI-associated myocarditis has a malignant course as 46% developed major adverse cardiac events over the next 3 to 6 months, including a 4-fold increased risk of MACE with troponin T of ≥1.5 ng/ml (hazard ratio: 4.0; 95% confidence interval: 1.5 to 10.9; p = 0.003).
|
|
|
|
Ferencik M., Hoffmann U. et al.: Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients with Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial. JAMA Cardiology 2018.
Dr. Hoffmann and colleagues determined whether high-risk plaque detected by coronary CTA was associated with incident MACE independently of significant stenosis and cardiovascular risk factors. The study included 4415 patients from 193 imaging sites across North America who were referred to coronary CTA with stable chest pain syndrome. The prevalence of high-risk plaque was 15% and was associated with a nearly 3 fold higher MACE rate (6.4% vs 2.4%; hazard ratio, 2.73; 95% CI, 1.89-3.93), and two fold increased MACE rate after adjustment for significant stenosis and cardiovascular risk factors ASCVD risk score and SS (adjusted hazard ratio (aHR), 1.72; 95% CI, 1.13-2.62). Most importantly, the study found that high-risk plaque could provide practice-changing optimizations in coronary artery disease care, especially in patients with nonobstructive coronary artery disease (aHR, 4.31; 95% CI, 2.25-8.26), younger patients (aHR, 2.33; 95% CI, 1.20-4.51), and women (aHR, 2.41; 95% CI, 1.25-4.64).
|
|
|
|
|
|
November and December 2018 Publications
|
|
|
Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.
Am Heart J. 2018
Pagidipati NJ, Coles A, Hemal K, Lee KL, Dolor RJ, Pellikka PA, Mark DB, Patel MR, Litwin SE, Daubert MA, Shah SH, Hoffmann U, Douglas PS; PROMISE Investigators.
|
|
|
|
Cheru LT, Fitch KV, Saylor CF, Lu M, Hoffmann U, Lo J, Grinspoon SK.
|
|
|
|
Vita T, Gräni C, Abbasi SA, Neilan TG, Rowin E, Kaneko K, Coelho-Filho O, Watanabe E, Mongeon FP, Farhad H, Rassi CH, Choi YL, Cheng K, Givertz MM, Blankstein R, Steigner M, Aghayev A, Jerosch-Herold M, Kwong RY.
|
|
|
|
Truong QA, Rinehart S, Abbara S, Achenbach S, Berman DS, Bullock-Palmer R, Carrascosa P, Chinnaiyan KM, Dey D, Ferencik M, Fuechtner G, Hecht H, Jacobs JE, Lee SE, Leipsic J, Lin F, Meave A, Pugliese F, Sierra-Galán LM, Williams MC, Villines TC, Shaw LJ; SCCT Women's Committee.
|
|
|
|
|
Foldyna B, Udelson JE, Karády J, Banerji D, Lu MT, Mayrhofer T, Bittner DO, Meyersohn NM, Emami H, Genders TSS, Fordyce CB, Ferencik M, Douglas PS, Hoffmann U.
|
|
|
|
Hsue PY, Li D, Ma Y, Ishai A, Manion M, Nahrendorf M, Ganz P, Ridker PM, Deeks SG, Tawakol A.
|
|
|
|
Stein JH, Yeh E, Weber JM, Korcarz C, Ridker PM, Tawakol A, Hsue PY, Currier JS, Ribaudo H, Mitchell CKC.
|
|
|
Chronic Stress-Related Neural Activity Associates With Subclinical Cardiovascular Disease in Psoriasis: A Prospective Cohort Study.
JACC Cardiovasc Imaging, 2018
Goyal A, Dey AK, Chaturvedi A, Elnabawi YA, Aberra TM, Chung JH, Belur AD, Groenendyk JW, Lerman JB, Rivers JP, Rodante JA, Harrington CL, Varghese NJ, Sanda GE, Baumer Y, Sorokin AV, Teague HL, Genovese LD, Natarajan B, Joshi AA, Playford MP, Bluemke DA, Chen MY, Alavi A, Pitman RK, Powell Wiley TM, Tawakol A, Gelfand JM, Mehta NN.
|
|
|
|
|
|
|
January and February Lab Meeting Schedule
175 Cambridge St, 4th Floor; 8:30-9:30am
Tuesday, January 1st
NO LAB MEETING: NEW YEARS
Tuesday, January 8th
Lili Zhang: "CMR in ICI myocarditis and immune therapy as a model of cardiovascular disease.”
Julia Karady: "Focal left ventricular intramyocardial fat on CT in stable chest pain - Insights from PROMISE trial.”
Tuesday, January 15th
Allen Jin: TBD
Nicki Naddaf: TBD
Tuesday, January 22nd
Michael Osborne: TBD
Sandeep Hedgire: TBD
Tuesday, January 29th
Max Schloss: TBD
Tuesday, February 5th
Raza Alvi: TBD
Tuesday, February 12th
Dahlia Banerji: TBD
Tuesday, February 29th
Vinit Baliyan: TBD
Max Schloss: TBD
Tuesday, February 26th
ECR Rehearsals
|
|
|
|
|
Thank you to everyone who came to the holiday party and made it such a success!
|
|
|
Sarah Mercaldo has availability to meet on Tuesdays between 11am - 3pm, and Wednesdays from 1pm - 4pm.
For sign-ups, please contact Devvora Olalere.
|
|
|
|
|
